Yoshizawa T, Yamakawa-Kobayashi K, Komatsuzaki Y, Arinami T, Oguni E, Mizusawa H, Shoji S, Hamaguchi H
Department of Neurology, University of Tsukuba, Japan.
Ann Neurol. 1994 Oct;36(4):656-9. doi: 10.1002/ana.410360416.
We examined the apolipoprotein E (apo E) genotypes in 47 patients with late-onset sporadic Alzheimer's disease (mean age at onset +/- standard deviation, 72.2 +/- 6.4 years), 8 with late-onset familial Alzheimer's disease (75.5 +/- 5.1 years), 18 with early-onset sporadic Alzheimer's disease (52.8 +/- 4.7 years), and 10 with early-onset familial Alzheimer's disease (52.0 +/- 6.8 years) in Japan and compared them with genotypes in control subjects. In late-onset sporadic Alzheimer's disease, apo E-epsilon 4 frequency increased significantly (epsilon 4 frequency: 0.34 vs 0.095 in controls, p < 0.0001), and the odds ratio, which represents the strength of association between Alzheimer's disease and apo E-epsilon 4, markedly increased with increasing dose of apo E-epsilon 4 gene (3 [95% confidence interval, 2-6] in one dose; 43 [95% confidence interval, 12-154] in two doses). This study also suggested that apo E-epsilon 4 is associated with both late-onset (epsilon 4: 0.31) and early-onset familial Alzheimer's disease (epsilon 4: 0.35). In contrast, we found no association between apo E-epsilon 4 and early-onset sporadic Alzheimer's disease (epsilon 4: 0.08). These results indicate that the risk of developing late-onset sporadic Alzheimer's disease is markedly dependent on the dose of apo E-epsilon 4, while apo E-epsilon 4 does not appear to be a major risk factor for early-onset sporadic Alzheimer's disease.
我们检测了日本47例晚发性散发性阿尔茨海默病患者(发病时平均年龄±标准差,72.2±6.4岁)、8例晚发性家族性阿尔茨海默病患者(75.5±5.1岁)、18例早发性散发性阿尔茨海默病患者(52.8±4.7岁)和10例早发性家族性阿尔茨海默病患者(52.0±6.8岁)的载脂蛋白E(apo E)基因型,并将其与对照受试者的基因型进行比较。在晚发性散发性阿尔茨海默病中,apo E-ε4频率显著增加(ε4频率:对照组为0.095,患者组为0.34,p<0.0001),代表阿尔茨海默病与apo E-ε4之间关联强度的优势比随着apo E-ε4基因剂量的增加而显著升高(一个剂量时为3[95%置信区间,2-6];两个剂量时为43[95%置信区间,12-154])。该研究还表明,apo E-ε4与晚发性(ε4:0.31)和早发性家族性阿尔茨海默病均有关联(ε4:0.35)。相比之下,我们发现apo E-ε4与早发性散发性阿尔茨海默病无关联(ε4:0.08)。这些结果表明,晚发性散发性阿尔茨海默病的发病风险显著取决于apo E-ε4的剂量,而apo E-ε4似乎不是早发性散发性阿尔茨海默病的主要风险因素。